Barriers and Challenges in Biomarker Testing for ALK+ NSCLC

Opinion
Video

Dr. Garon discusses the factors that make a patient a strong candidate for ALK inhibitor therapy in ALK+ NSCLC, the importance of biomarker testing in guiding treatment selection, and his approach to testing along with challenges encountered, especially in community settings.

This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with ALK+ non-small cell lung cancer as seen in clinical practice. The hypothetical case was co-developed by staff Medical Writers with Cancer Network/ONN.

  1. Dr. Thawani asks Dr Garon: What factors make this patient a strong candidate for ALK inhibitor therapy?
  • How critical is biomarker testing in guiding treatment selection?
  • Could you share your approach to biomarker testing and any barriers faced, particularly in community settings?

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
2 experts in this video
2 experts in this video
2 experts are featured in this series.
2 experts are featured in this series.
4 experts in this video
2 experts in this video
Related Content